QMENTA is a technology company.
QMENTA has raised $3.0M across 1 funding round.
QMENTA has raised $3.0M in total across 1 funding round.
QMENTA is a technology company specializing in cloud-based AI solutions for medical imaging, primarily focused on brain data analysis using MRI and related clinical data. It provides an integrated platform that streamlines the management, processing, and analysis of complex neuroimaging data to accelerate drug development and improve patient diagnosis and treatment decisions. Its products serve biopharmaceutical companies, medical device firms, research institutions, and clinicians by offering AI-powered imaging biomarkers, data harmonization, and clinical trial imaging management tools. QMENTA addresses the challenge of fragmented and manual neuroimaging workflows by automating image analysis, reducing costs, and enhancing precision and reproducibility in neurological disease research and clinical trials[1][3][4].
Founded in 2013 by a team of expert neuroscientists, QMENTA emerged from the vision to transform brain disease diagnosis and treatment through advanced imaging technology. The founders recognized the need for a scalable, collaborative cloud platform that could organize and quantify brain imaging data transparently and objectively. Early traction came from partnerships with leading research institutions and pharmaceutical companies, enabling QMENTA to develop proprietary AI algorithms and a marketplace of imaging biomarkers. The company’s involvement in initiatives like #ConquerCovid, where it provided a centralized AI-powered imaging platform for COVID-19 research, marked pivotal moments demonstrating its capacity to support large-scale, collaborative medical imaging efforts[1][3].
QMENTA rides the growing trend of applying AI and cloud computing to medical imaging, particularly in neurological disease research and clinical trials. The timing is critical as the healthcare industry increasingly demands objective, scalable, and automated imaging solutions to handle large datasets and complex analyses. Market forces such as aging populations, rising neurological disease prevalence, and the push for precision medicine favor QMENTA’s offerings. By enabling faster drug development and more accurate patient monitoring, QMENTA influences the broader ecosystem by setting new standards for imaging data management and AI integration in clinical research[1][3][4].
Looking ahead, QMENTA is poised to expand its AI biomarker library and deepen integration with pharmaceutical and medical device workflows, further accelerating neurological drug development and personalized medicine. Trends such as increased adoption of AI in healthcare, cloud-based collaboration, and regulatory acceptance of AI tools will shape its journey. Its influence may evolve from a specialized neuroimaging platform to a broader leader in AI-powered medical imaging across multiple therapeutic areas, continuing to reduce costs and improve clinical outcomes. This aligns with its founding vision of a future where brain diseases can be better diagnosed, treated, or even prevented[1][4][7].
QMENTA has raised $3.0M in total across 1 funding round.
QMENTA's investors include BioVentures Investors, Cyberlaunch.
QMENTA has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in May 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2017 | $3.0M Seed | BioVentures Investors, Cyberlaunch |